ArticleBMC oral health2026
Cuspal displacement, marginal adaptation, and nanoleakage in maxillary premolars restored with a novel auto-cured bulk-fill composite versus a light-cured bulk-fill composite: an in-vitro study.
Article in BMC oral health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSTELA is a newly introduced auto-cured bulk-fill composite proposed as an alternative to amalgam. It does not require light activation and provides an unlimited depth of cure, in addition to acceptable esthetic and mechanical properties.
objectivesTo evaluate cuspal displacement, marginal adaptation, and nanoleakage in mesio-occluso-distal (MOD) Class II preparations of maxillary premolars restored with an auto-cured bulk-fill composite compared with a light-cured bulk-fill composite. MATERIALS AND
methodsSixty maxillary human premolars extracted for orthodontic purposes were randomly assigned to two groups (n = 30) according to the bulk-fill composite used. Standardized MOD Class II preparations were made and restored using either Group 1: STELA Capsule (SDI, Australia) or Group 2: Tetric N-Ceram Bulk Fill (Ivoclar Vivadent, Liechtenstein). Each group was subdivided into three subgroups (n = 10) based on the test performed. In Subgroup 1, cuspal displacement was recorded after post-cavity preparation and at (5 min, 24 h) post-restoration using a digital microscope. The remaining restored specimens underwent thermocycling and mechanical loading. Subsequently, marginal adaptation (Subgroup 2) was examined using scanning electron microscopy. Nanoleakage (Subgroup 3) was evaluated using silver nitrate tracing. Statistical analysis was performed using the independent-samples t-test and Fisher's exact test (P ≤ 0.05).
resultsSTELA Capsule demonstrated significantly lower cuspal displacement at both 5 min and 24 h post-restoration compared with Tetric N-Ceram Bulk Fill (P < 0.001). Following thermocycling and mechanical loading, STELA Capsule also exhibited better marginal adaptation (P = 0.033) and reduced nanoleakage (P < 0.001) compared with the Tetric N-Ceram Bulk Fill.
conclusionsThe STELA composite with its dedicated primer showed favorable laboratory outcomes compared with Tetric N-Ceram Bulk Fill used with Tetric N-Bond. This restorative protocol can serve as a viable clinical alternative to light-cured bulk-fill composites, particularly for restoring MOD Class II preparations in maxillary premolars. CLINICAL RELEVANCE: The novel auto-cured bulk-fill composite with its dedicated primer demonstrated excellent performance in reinforcing weakened premolars. It exhibited superior results in reducing cuspal displacement, improving marginal adaptation, and minimizing nanoleakage compared to a light-cured bulk-fill composite, indicating its potential for clinical use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.